Use of erythropoietin-stimulating agents in breast cancer patients: A risk review

American Journal of Health-System Pharmacy

Volumn 66, Issue 13, 2009, Pages 1180-1185

  Crouch, Zachary ^a   Hermes DeSantis, Evelyn R ^a,b  

^a RUTGERS UNIVERSITY   (United States)

^b ROBERT WOOD JOHNSON UNIVERSITY HOSPITAL   (United States)

Author keywords

Anemia; Breast neoplasms; Darbepoetin alfa; Dosage; Epoetin alfa; Hematopoietic agents; Quality of life; Toxicity

Indexed keywords

ANTIANEMIC AGENT; ERYTHROPOIETIN STIMULATING AGENT; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ERYTHROPOIETIN;

ANEMIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER PATIENT; CLINICAL TRIAL; DEATH; DISEASE COURSE; DRUG EFFICACY; ERYTHROCYTE TRANSFUSION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LOW DRUG DOSE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT SAFETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SCORING SYSTEM; SURVIVAL TIME; VENOUS THROMBOEMBOLISM; BLOOD TRANSFUSION; BREAST TUMOR; DRUG EFFECT; DRUG LABELING; DRUG MONITORING; FEMALE; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE;

ANEMIA; BLOOD TRANSFUSION; BREAST NEOPLASMS; DRUG LABELING; DRUG MONITORING; EPOETIN ALFA; ERYTHROPOIETIN; FEMALE; HEMATINICS; HEMOGLOBINS; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 70349252039     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp080214     Document Type: Review

References (15)

1. Ries LG, Melbert D, Krapcho M et al. National Cancer Institute. SEER cancer statistics review, 1975-2005. http://seer.cancer.gov/csr/1975-2005/ (accessed 2009 Feb 27).
2. DiPiro JT. Pharmacotherapy: a pathophysiologic approach. Chap. 124. Cancer treatment and chemotherapy. 6th ed. Chicago: McGraw Hill; 2005:2321-2323
3. Johnston E, Crawford J. The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds. Principles and practice of supportive oncology, 2nd ed. Philadelphia: Lippincott-Raven; 2002:549-555
4. Littlewood TJ, Bajetta E, Nortier JW et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol. 2001; 19:2865-2874 (Pubitemid 32538196)
5. Seidenfeld J, Piper M, Flamm C et al. Epoetin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J Natl Cancer Inst. 2001; 93:1204-14. (Pubitemid 32816195)
6. Chang J, Couture F, Young S et al. Weekly epoetin alfa maintains hemoglobin, improves quality of life, and reduces transfusion in breast cancer patients receiving chemotherapy. J Clin Oncol 2005; 23:2597-2605 [Erratum, J Clin Oncol. 2005; 23:5276.] (Pubitemid 46179448)
7. Cella D. The Functional Assessment of Cancer Therapy - Anemia (FACT-AN) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol. 197; 34(3, suppl 2):13-19
8. Demetri GD, Kris M, Wade J et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J Clin Oncol. 1998; 16: 3412-3425 (Pubitemid 28481641)
9. Claspy J, Burkowski R, Sternberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. J Clin Oncol. 1997; 15: 1218-1234
10. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol. 2005; 23:5960-72. (Pubitemid 46300213)
11. Data on file for PREPARE trial. Thousand Oaks, CA: Amgen; 2008.
12. Bennett C, Silver S, Djulbegovic B et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008; 299:914-924
13. Procrit (epoetin alfa) package insert. Bridgewater, NJ: Ortho Biotech Inc.; 2008.
14. Crawford J, Cella D, Cleeland CS et al. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002; 95:888-895 (Pubitemid 34839682)
15. Littlewood TJ, Zagari M, Pallister C et al. Baseline and early treatment factors are not clinically useful for predicting individual response to erythropoietin in anemic cancer patients. Oncologist. 2003; 8:99-107.